top of page
Hephaistos Pharma
Hephaistos is developing innate immunity modulators capable of transforming immuno-resistant ‘cold’ tumours into ‘hot’ tumours by modifying their micro-tumour environment. The company has obtained preclinical proof-of-concept for the first systemic TLR4 activator with efficacy against primary tumours and metastases, alone and in combination. The HEPHA-440 drug candidate has received orphan drug designation for the treatment of osteosarcoma and is expected to enter the clinic by 2027.
PSCC's entrance
Décembre 2025
Localization
FR - Île-de-France
Modality
Immunotherapy
Development status
Biotech - Pre-IND/Pre-CTA
Lauréat (s)
iLAB, iNov, EIC laureate, RHU
bottom of page



